Stocktoria
Quince Therapeutics, Inc. QNCX
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-09
Quince Therapeutics, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D expense | $35.4M | $18.6M | $9.4M | $25.2M | $60.8M | $61.3M | $30.2M | $10.1M |
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M | -$78.9M | -$39.2M | -$12.1M |
| Interest expense | — | — | — | — | — | — | — | $957,000 |
| Income tax | $3.2M | $87,000 | -$197,000 | -$284,000 | $0 | $0 | $0 | $0 |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M | -$89.9M | -$76.8M | -$37.0M | -$12.5M |
| EPS (diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | — | — | — |
| Operating cash flow | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M | -$50.8M | -$33.3M | -$11.7M |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M | -$50.9M | -$33.3M | -$11.9M |
| Cash & equivalents | $5.8M | $6.2M | — | $40.6M | $29.5M | — | $51.2M | $24.9M |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M | $189.5M | $124.4M | $72.9M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | $14.6M | $17.2M | $8.9M | $1.5M |
| Shareholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M | $118.6M | $172.3M | $115.5M | -$32.6M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.